我武生物(300357.SZ)：获得豚草花粉点刺液药物临床试验补充申请批准通知书

Core Viewpoint - The company, Iwu Biologics (300357.SZ), has received approval for a supplementary application for clinical trials of its drug "Artemisia Pollen Puncture Solution" from the National Medical Products Administration, indicating progress in its product development pipeline [1] Group 1 - The approved clinical trial is aimed at diagnosing Type I hypersensitivity diseases related to ragweed pollen allergy through skin prick tests [1]